Alopexx reports Phase I data for bacterial infection prevention candidate

In October, Alopexx Vaccine LLC (Concord, Mass.) reported data from a Phase I trial in 16 healthy volunteers showing that 75-150 μg doses of bacterial infection prevention candidate AV0328 were well tolerated. Alopexx said the 75 and 150 μg doses led to increases in antibody titers against poly-N-acetyl glucosamine (PNAG), as well as a “positive indication” of protective immunity as measured by complement activation and binding to the PNAG antigen. The company also said AV0328 led to “robust bactericidal killing” of Neisseria gonorrhea and N. meningitidis, as well as opsonic killing of Streptococcus pneumoniae, Klebsiella pneumonia, Escherichia coli and Staphylococcus aureus...